LightWave Acquisition Corp. Class A Ordinary Shares (LWAC)

Shares of Locust Walk Acquisition Corp (NASDAQ: LWAC) are surging higher Wednesday morning after the merger with eFFECTOR Therapeutics was approved. eFFECTOR Therapeutics is focused on selective translation regulation inhibitors to treat cancer. The SPAC merger valued the company at $419 million, including a $60 million PIPE with an investment from Pfizer Inc's (NYSE: PFE) venture capital arm Pfizer Ventures. Related Link: Exclusive: Accelerate CEO On SPAC Arbitrage, Why You Can't Always Bet On SPAC Sponsor Why The Stock Is Soaring: Locust Walk Acquisition raised $175 million in its IPO, selling 17.5 ...